

## **DIASORIN S.P.A. – UPDATE 2024 ANNUAL CALENDAR OF CORPORATE EVENTS\***

**Saluggia, September 5, 2024** – Updating the notice published on April 4, 2024, please find below the the new scheduled date for the approval of the Third Quarter 2024 results approval.

### **Board of Directors**

<b>November 5, 2024</b>	<b>Third Quarter 2024 results approval</b>
-------------------------	--

\* Indicative dates subject to change. Any changes will be communicated without delay.

The conference call for the presentation of the financials results to the investors will take place, as in the past, on the same day of the approval by the Board of Directors. The timing will be communicated as soon as scheduled.

### **About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasorin.com](http://www.diasorin.com)

### **FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

#### **INVESTOR RELATIONS**

##### **Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.com](mailto:riccardo.fava@diasorin.com)

##### **Eugenia Ragazzo**

Corporate Investor Relations & ESG Analyst  
[eugenia.ragazzo@diasorin.com](mailto:eugenia.ragazzo@diasorin.com)